Teacher Retirement System of Texas Boosts Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Teacher Retirement System of Texas increased its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 60.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,415 shares of the biopharmaceutical company’s stock after acquiring an additional 24,615 shares during the period. Teacher Retirement System of Texas’ holdings in Lexicon Pharmaceuticals were worth $48,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Intech Investment Management LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter worth $115,000. Charles Schwab Investment Management Inc. boosted its position in shares of Lexicon Pharmaceuticals by 4.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 58,147 shares during the last quarter. FMR LLC increased its holdings in Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after buying an additional 11,179,919 shares in the last quarter. BNP Paribas Financial Markets raised its position in Lexicon Pharmaceuticals by 71.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 13,246 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter worth $189,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $0.50 on Thursday. The business has a 50 day simple moving average of $0.59 and a 200-day simple moving average of $0.97. The firm has a market capitalization of $123.88 million, a PE ratio of -0.67 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.28 and a 1 year high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. The company had revenue of $26.55 million during the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. Equities research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LXRX. Leerink Partnrs cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Piper Sandler decreased their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. StockNews.com initiated coverage on Lexicon Pharmaceuticals in a research report on Friday, March 28th. They set a “sell” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.67.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.